Vizgen
PrivateLast Round
Series E
Jan 8, 2026
Total Funding Raised
$328.7M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vizgen is a biotechnology company that provides spatially resolved, single-cell gene expression profiling tools to enhance understanding of biological systems and diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Medical Imaging, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales, Services & Consulting, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vizgen Comparables
Compare Vizgen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Resolve Biosciences | 84% | |
| Stellaromics | 83% | |
| 10x Genomics | 81% |
Vizgen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Jan 8, 2026 | ||||
| Series D | Oct 9, 2024 | ||||
| Growth Equity | Mar 8, 2024 | ||||
| Series C | Jun 3, 2022 | ||||
| Series B | Jul 20, 2021 | ||||
Series B | Apr 7, 2021 |
Vizgen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ARCH Venture Partners | Series B, Series D, Series C, Series A, Series E |
| M Ventures | Series D, Series E |
| Northpond Ventures | Series C, Series D, Series B, Series A, Series E |
| ARCH Venture Partners | Series B, Series D, Series C, Series A, Series E |
| Blue Water Life Science Advisors | Series C |
| Novalis LifeSciences | Series C, Series B |
| Northpond Ventures | Series C, Series D, Growth Equity, Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 8, 2026
$48M Series E round completed.
- Nov 17, 2025
Collaboration with Ultivue to serve big pharma customers and CROs.
Vizgen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vizgen's valuation, stock price, and market status.
Is VIZGEN a public or private company?
VIZGEN is a private company.
What is the current stock price of VIZGEN?
VIZGEN is a private company with no public stock price. No recent secondary market data is available.
How much is VIZGEN worth (valuation)?
Valuation information for VIZGEN is not publicly available.
Can I buy VIZGEN stock?
VIZGEN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was VIZGEN's last funding round?
VIZGEN's most recent funding round was Series E on January 8, 2026.
Who are the main investors in VIZGEN?
Key investors in VIZGEN include ARCH Venture Partners, M Ventures, Northpond Ventures, ARCH Venture Partners, Blue Water Life Science Advisors.
Will VIZGEN IPO soon?
No public IPO plans have been announced for VIZGEN.
How can I track VIZGEN secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VIZGEN's secondary market activity and sign up for updates.